{
    "clinical_study": {
        "@rank": "21885", 
        "arm_group": {
            "arm_group_label": "The condition of rheumatoid arthritis", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis\n      patients"
        }, 
        "brief_title": "Evaluation of the Condition of Rheumatoid Arthritis After Treatment", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Rheumatoid arthritis\n\n        Exclusion Criteria:\n\n          -  Other connective tissue disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02157012", 
            "org_study_id": "Xeljanz2014"
        }, 
        "intervention": {
            "arm_group_label": "The condition of rheumatoid arthritis", 
            "intervention_name": "The effectiveness of Xeljanz in rheumatoid arthritis patients", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "yxn14@aol.jp", 
                "last_name": "Yukio Nakamura, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Matsumoto", 
                    "country": "Japan", 
                    "state": "Nagano", 
                    "zip": "3908621"
                }, 
                "name": "Yukio Nakamura"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients", 
        "overall_contact": {
            "email": "yxn14@aol.jp", 
            "last_name": "Yukio Nakamura, MD, PhD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DAS28, SDAI, Blood testing, Plain radiograph, and Ultrasound will be performed.", 
            "measure": "Change from baseline of clinical evaluation in rheumatoid arthritis", 
            "safety_issue": "Yes", 
            "time_frame": "Every month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02157012"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shinshu University", 
            "investigator_full_name": "Yukio Nakamura", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Every month"
        }, 
        "source": "Shinshu University", 
        "sponsors": {
            "collaborator": {
                "agency": "Showa Inan General Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shinshu University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}